<seo title="Gilead Sciences" metakeywords="gilead sciences,introduction gilead sciences,gilead sciences biopharmaceutical,history gilead sciences" metadescription="Gilead Sciences is a biopharmaceutical company based in Foster City, California."/>
===Introduction to Gilead Sciences===
Gilead Sciences is a biopharmaceutical company based in Foster City, California. Founded in 1987, Gilead Sciences is a leader in the development, manufacture, and commercialization of innovative therapeutics for the treatment of life-threatening diseases. Gilead Sciences has a broad portfolio of products and services, including antiviral, oncology, and cardiovascular therapies. Gilead Sciences is committed to providing innovative treatments to improve the lives of patients around the world.
===History of Gilead Sciences===
Gilead Sciences was founded in 1987 by Michael  Riordan, a former professor of medicine at Stanford University. The company was initially focused on the development of antiviral drugs, and in 1990, Gilead Sciences received its first FDA approval for its antiviral drug, Vistide. Since then, Gilead Sciences has grown to become a leader in the biopharmaceutical industry, with a portfolio of more than 20 approved drugs and a pipeline of more than 40 investigational drugs.
===Financial Performance of Gilead Sciences===
Gilead Sciences has a strong [[Financial Performance|financial performance]], with total revenues of $22.2 billion in 2020. The company has a strong [[Balance Sheet|balance sheet]], with total assets of $41.3 billion and [[Total Liabilities|total liabilities]] of $14.2 billion. Gilead Sciences has a strong cash position, with [[Cash And Cash Equivalents|cash and cash equivalents]] of $7.3 billion as of December 31, 2020. The company has a strong [[Return On Equity|return on equity]] of 17.2%, and a [[Return On Assets|return on assets]] of 8.2%.
===Products and Services of Gilead Sciences===
Gilead Sciences has a broad portfolio of products and services, including antiviral, oncology, and cardiovascular therapies. The company’s antiviral products include Viread, Truvada, and Vosevi. Gilead Sciences’ oncology products include Zydelig, Yescarta, and Tecartus. The company’s cardiovascular products include Letairis, Ranexa, and AmBisome. Gilead Sciences also offers services such as clinical trials, drug discovery, and drug development.
===Corporate Governance of Gilead Sciences===
Gilead Sciences is committed to strong [[Corporate Governance|corporate governance]] practices. The company’s [[Board Of Directors|board of directors]] is composed of 11 members, including the chairman and CEO, John F. Milligan. The board of directors is responsible for overseeing the company’s strategic direction and ensuring that the company is compliant with applicable laws and regulations. The board of directors also sets the company’s compensation policies and reviews the performance of the company’s executive officers.
===Conclusion===
Gilead Sciences is a biopharmaceutical company that is committed to providing innovative treatments to improve the lives of patients around the world. The company has a strong financial performance, with total revenues of $22.2 billion in 2020. Gilead Sciences has a broad portfolio of products and services, including antiviral, oncology, and cardiovascular therapies. The company is also committed to strong corporate governance practices,